Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro
Open Access
- 31 May 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 591
Abstract
Cytochrome P450 3A4 (CYP3A4) enzyme activity is known to show considerable ethnic heterogeneity and inter-individual differences, affecting the outcome of drug treatment. CYP3A4 genetic polymorphisms are believed to be one of the important causes, leading to inter-individual variability in drug metabolism. Quinine is an antipyretic drug with antimalarial properties that is metabolized primarily by CYP3A4. Quinine 3-hydroxylation has been proven as a biomarker reaction for evaluating CYP3A4 ability. Quinine has frequent adverse effects and there are distinct inter-individual differences in quinine sensitivity. The open reading frame for 30 CYP3A4 allelic variants were constructed from wild-type CYP3A4*1A by an overlap extension polymerase chain reaction. Recombinant CYP3A4 variants were expressed using baculovirus-insect cell expression system, and their catalytic activities towards quinine hydroxylation were determined and evaluated. Of the 30 CYP3A4 allelic variants, 23 variants exhibited significantly reduced intrinsic clearance towards quinine, 2 variants showed increased intrinsic clearance for quinine, 2 variants possessed no significant differences towards quinine, compared with CYP3A4*1A, and 3 variants had no detected expression and enzyme activity. Our assessment on the enzymatic activities of CYP3A4 variants towards quinine may contribute to laying an experimental foundation for further clinical studies so as to accelerate the process of determining the associations between genetic variations and clinical phenotypes.Keywords
This publication has 46 references indexed in Scilit:
- Pharmacogenetics, Pharmacogenomics, and Individualized MedicinePharmacological Reviews, 2011
- Quinine, an old anti-malarial drug in a modern world: role in the treatment of malariaMalaria Journal, 2011
- Analysis of CYP3A4 genetic polymorphisms in Han ChineseJournal of Human Genetics, 2011
- CYP3A4*16 and CYP3A4*18 Alleles Found in East Asians Exhibit Differential Catalytic Activities for Seven CYP3A4 Substrate DrugsDrug Metabolism and Disposition, 2010
- Tacrolimus Concentrations in Relation to CYP3A and ABCB1 Polymorphisms Among Solid Organ Transplant Recipients in KoreaTransplantation, 2009
- Functional characterization of CYP3A4.16: Catalytic activities toward midazolam and carbamazepineXenobiotica, 2009
- Defective Activity of Recombinant Cytochromes P450 3A4.2 and 3A4.16 in Oxidation of Midazolam, Nifedipine, and TestosteroneDrug Metabolism and Disposition, 2008
- The CYP3A4*18 Allele, the Most Frequent Coding Variant in Asian Populations, Does Not Significantly Affect the Midazolam Disposition in Heterozygous IndividualsDrug Metabolism and Disposition, 2007
- Phenotype–genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 allelesBiochemical and Biophysical Research Communications, 2005
- Recombinant CYP3A4*17 Is Defective in Metabolizing the Hypertensive Drug Nifedipine, and the CYP3A4*17 Allele May Occur on the Same Chromosome as CYP3A5*3, Representing a New Putative Defective CYP3A HaplotypeThe Journal of Pharmacology and Experimental Therapeutics, 2005